In the BioHarmony Drug Report Database

"Preview" Icon

Tazarotene

Arazlo, Avage, Fabior, Tazorac (tazarotene) is a small molecule pharmaceutical. Tazarotene was first approved as Arazlo on 1997-06-13. It is used to treat acne vulgaris and psoriasis in the USA. The pharmaceutical is active against retinoic acid receptor beta, retinoic acid receptor alpha, and retinoic acid receptor gamma. In addition, it is known to target chemokine-like receptor 1 and G-protein coupled receptor 1. Tazorac’s patent is valid until 2030-02-24 (FDA).

 

Trade Name

 

Arazlo, Avage, Fabior, Tazorac
 

Common Name

 

tazarotene
 

ChEMBL ID

 

CHEMBL1657
 

Indication

 

acne vulgaris, psoriasis
 

Drug Class

 

Arotinoid derivatives

Image (chem structure or protein)

Tazarotene structure rendering